HOME - Companies - Products
13 March 2024

Implant Dentistry Without Peri-Implantitis at the AO Annual Meeting

This week, from March 7th to 9th, the 2024 Annual Meeting of the Academy of Osseointegration (AO) will commence at the Convention Center in Charlotte, North Carolina. The theme of this year’s conference, “Going beyond the Boundaries – Optimizing Patient Care Through Scientific and Clinical Innovation,” resonates with the Swiss Implant System Patent committed to preventing peri-implantitis. The key to success: the implant’s unique combination of specialized surface topography, soft-tissue level design, and exclusive material composition, which facilitates strong and intimate soft-tissue adhesion – providing an ideal defense barrier against bacteria (Fig. 1).

The Patent System’s success in preventing peri-implantitis is backed by long-term scientific evidence.

“The nightmare of implant dentistry”

Commenting on the results of meta-analyses and discourse at dental congresses worldwide, Marco Waldner, founder and CEO of Patent, recently described peri-implantitis as “the nightmare of implant dentistry.” It is estimated that 22% (weighted mean) of implants will be affected by peri-implantitis during their functional lifespan. The prevalence of peri-implant mucositis—the chronic inflammation of the soft tissue, the condition preceding peri-implantitis—is even higher, around 43%–47%.1,2 Considering the growing number of patients choosing dental implants as their primary solution for tooth replacement, the implications of this complication are alarming: Once established, peri-implantitis is difficult to treat and in many cases ends in implant loss.3 The significance of the topic is underscored by its inclusion in the opening symposium of the AO Meeting.

No peri-implantitis after 9 and up to 12 years

Two new independent long-term studies, conducted at the universities of Düsseldorf (Germany) and Graz (Austria), have now confirmed the long-term success of the two-piece Patent™ Implant in preventing peri-implantitis.4,5 In the latter study, Dr. Sofia Karapataki in collaboration with Dr. Harald Fahrenholz from Vienna followed up 91 Patent Implants placed in 39 patients for 5 and up to 12 years of function, paying particular focus on the occurrence of biological complications. This study intentionally included patients encountered in daily practice, who presented general health conditions such as cancer, Down’s syndrome or MS, who suffered from periodontitis, or were (heavy) smokers. The results were published in the International Journal of Oral and Maxillofacial Implants, one of the highest-impact journals in the dental world.

Study findings at a glance:

  • No peri-implantitis – even in compromised patients
  • Survival and success rates of 100%6,7
  • Only minor prosthetic and biological complications: Only 3 patients (7.7%; 9 implants) with symptoms of peri-implant mucositis. No marginal bone loss or only slight changes of bone level (< 0.7 mm) in 85 implants. Six implants with bone loss of more than 0.7 mm. Maximum marginal bone loss of 1.67 mm
  • Healthy soft tissue in 36 patients (81 implants)

Study author Dr. Karapataki concluded: “The study documents outstanding long-term results achieved with the implant system investigated – including ‘real-life’ patients whom I treat in my practice on a daily basis. This offers hope for more implant treatments without peri-implantitis in daily practice.”

In light of these results, Marco Waldner is convinced: “The prevention of peri-implantitis starts with the dentists’ choice of implant system – this is exactly where Patent comes into play.”

Discover Patent at the AO Meeting

Attendees of this year’s AO Annual Meeting will have the exclusive opportunity to learn more about the results of the long-term studies on Patent Dental Implants from Paul Delgado (Director International Sales at Patent) and Gerry Romanescu (Manager Customer Experience). Make sure to visit the Patent booth during the conference to explore the implications of the study findings for daily implant practice and to understand why Patent™ can achieve such remarkable long-term biological success.

Source: www.mypatent.com

Related articles

The new Affordable Dentures & Implants practice in Cedar Park, Texas, located at 1890 Ranch, 1335 E. Whitestone Blvd., Bldg. D, Suite 145, is now open. The practice joins the nation’s largest...

Glidewell recently announced a rebrand of its flagship Hahn Tapered Implant System, now known as the Glidewell HT Implant System.

DEXIS™IS ScanFlow v.1.0.10 adds a new series of guided workflows and AI enhancements as well as a two-way integration with DEXIS 10 to optimize dental implant workflows.

The prevalence of hypertension among adults aged 30 to 79 in 2019 was 32% in women and 34% in men, making it one of the most common chronic medical conditions worldwide and a leading cause of...

The longevity of teeth, dental restorations and dental implants is influenced by a number of factors, those related to the materials used, technical factors and patient-related factors. 

Read more

Dental autotransplantation (AT) is defined as the transplantation of a tooth from one site to a different site in the oral cavity of the same individual. 

Born and raised in Havana, Cuba, Layra Valdes, DMD24, first became interested in dentistry when her orthodontist showed how her dental experience could be fun and educational rather than scary and...

Pearl announced that Software of Excellence, a leader in dental software, has selected Pearl as its new, exclusive dental artificial intelligence (AI) provider.

DEXIS presents the latest innovation to its digital ecosystem with an all-new dental intraoral sensor, the DEXIS Ti2 Sensor. The DEXIS digital ecosystem is a comprehensive, AI-powered platform for...

Millennials, also known as "Gen Y," and Gen Z are redefining the boundaries of consumption and savings. 



Most popular